Andrew J. Wallace

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Dominic G. Rothwell, Mahmood Ayub, Natalie Cook et al. · Nature Medicine · 2019 · 302 citations

Genetic Testing, Oncology, Cancer Detection +11

Predictors of the Risk of Mortality in Neurofibromatosis 2

Michael E. Baser, Jan M. Friedman, Dana Aeschliman et al. · The American Journal of Human Genetics · 2002 · 225 citations · Full text

Neuro-oncology, Fibrosis, Disease Progression +6

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

D. Gareth Evans, L. Trueman, Andrew J. Wallace et al. · Journal of Medical Genetics · 1998 · 222 citations · Full text

Evaluation of clinical diagnostic criteria for neurofibromatosis 2

M E Baser, Jan M. Friedman, Andrew J. Wallace et al. · Neurology · 2002 · 221 citations

Molecular characterisation of <i>SMARCB1</i> and <i>NF2</i> in familial and sporadic schwannomatosis

Kristin Hadfield, William G. Newman, Naomi L. Bowers et al. · Journal of Medical Genetics · 2008 · 204 citations